Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.
Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN. Schott AF, et al. Among authors: barlow we. Breast Cancer Res Treat. 2016 Aug;159(1):87-95. doi: 10.1007/s10549-016-3911-z. Epub 2016 Jul 30. Breast Cancer Res Treat. 2016. PMID: 27475087 Free PMC article. Clinical Trial.
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S; Southwest Oncology Group/Intergroup Study 9623. Moore HC, et al. Among authors: barlow we. J Clin Oncol. 2007 May 1;25(13):1677-82. doi: 10.1200/JCO.2006.08.9383. Epub 2007 Apr 2. J Clin Oncol. 2007. PMID: 17404368 Clinical Trial.
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF. Tubbs R, et al. Among authors: barlow we. J Clin Oncol. 2009 Aug 20;27(24):3881-6. doi: 10.1200/JCO.2008.20.1566. Epub 2009 Jul 20. J Clin Oncol. 2009. PMID: 19620488 Free PMC article.
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.
Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. Choi JY, et al. Among authors: barlow we. Clin Cancer Res. 2009 Aug 15;15(16):5258-66. doi: 10.1158/1078-0432.CCR-09-0685. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671875 Free PMC article. Clinical Trial.
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, Hayes DF, Albain KS. Ambrosone CB, et al. Among authors: barlow we. J Clin Oncol. 2009 Oct 20;27(30):4973-9. doi: 10.1200/JCO.2009.21.8669. Epub 2009 Sep 14. J Clin Oncol. 2009. PMID: 19752340 Free PMC article. Clinical Trial.
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK; Breast Cancer Intergroup of North America. Albain KS, et al. Among authors: barlow we. Lancet. 2009 Dec 19;374(9707):2055-2063. doi: 10.1016/S0140-6736(09)61523-3. Epub 2009 Dec 10. Lancet. 2009. PMID: 20004966 Free PMC article. Clinical Trial.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America. Albain KS, et al. Among authors: barlow we. Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10. Lancet Oncol. 2010. PMID: 20005174 Free PMC article.
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Harigopal M, et al. Among authors: barlow we. Am J Pathol. 2010 Apr;176(4):1639-47. doi: 10.2353/ajpath.2010.090711. Epub 2010 Feb 11. Am J Pathol. 2010. PMID: 20150438 Free PMC article. Clinical Trial.
290 results